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Abstract
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms 
of the gastrointestinal tract, occurring predominantly in the stomach and small intestine. 
These tumors account for up to 3% of all gastrointestinal malignancies, with a reported 
annual incidence of 10–15 cases per million population. GISTs are thought to originate 
from interstitial cells of Cajal (ICC) or ICC precursor cells, and are characterized by acti-
vating mutations in the KIT (CD117) and platelet-derived growth factor receptor alpha 
(PDGFRα) proto-oncogenes in 85–95% of all cases. The clinical presentation and tumor 
biology of GISTs are widely variable, with several advances being made over the past two 
decades in the understanding of GIST tumor biology and pathophysiology. This has led 
to a paradigm shift in management from the purely surgical approach of the past, to a 
multi-modality treatment strategy with a greater role for targeted therapies in the form of 
tyrosine kinase inhibitors, resulting in significantly improved patient outcomes.
Keywords: gastrointestinal stromal tumor (GIST), stromal tumors, gastric tumors, 
KIT mutation, imatinib
1. Introduction
Gastrointestinal stromal tumors (GIST) represents the most common mesenchymal tumor of 
the gastrointestinal (GI) tract, accounting for up to 3% of all GI malignancies [1, 2]. The his-
tory of GIST dates back several decades, with early classifications including GI schwannomas, 
leiomyomas, leiomyoblastomas and leiomyosarcomas based on the histological findings and 
variable differentiation associated with these tumors. With advances in immunohistochemical 
staining techniques and improvements in microscopic structural imaging, GISTs became rec-
ognized as a distinct entity. Although the term GIST was originally coined in 1983 by Mazur 
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and Clark, it was not until 1998 that Hirota et al. discovered a gain-of-function mutation in the 
KIT proto-oncogene associated with GISTs [3, 4]. This finding led to a greater understanding 
of these tumors, and an eventual reclassification of GI sarcomas.
The reported annual incidence of GIST is 10–15 cases per million population, with over 5000 
new cases being diagnosed each year within the United States [5–8]. GISTs can occur at any 
age, however, more than 80% have been reported in individuals over 50, with the median 
age of presentation at 63 years old [9, 10]. Most studies have reported no significant gender 
predilection, with a few studies identifying a slight male predominance [7, 8, 11]. While GISTs 
can occur anywhere along the GI tract, they are most commonly found in the stomach (50%), 
followed by small intestine (36%), colon (7%), rectum (5%) and esophagus (1%) [12–14]. In 
rare instances, primary GISTs are identified outside of the GI tract, including the omentum, 
retroperitoneum and mesentery. These account for <5% of all GISTs and are termed extra-
gastrointestinal stromal tumors (E-GIST), and could represent metastasis from an undetected 
primary tumor [13, 15].
Immunophenotypically, GISTs have a close resemblance to the interstitial cells of Cajal (ICC), 
the pacemaker cells of the intestine, suggesting that they either originate from ICC or from 
ICC precursor cells, both of which express type III tyrosine kinase receptors [14]. Activating 
mutations in the KIT (CD117) and platelet-derived growth factor receptor alpha (PDGFRα) 
proto-oncogenes are responsible for 85–95% of all GISTs [15]. The vast majority of GISTs occur 
sporadically, with approximately 5% occurring in the setting of syndromes, most commonly 
Neurofibromatosis type 1 [16]. Less frequently associated syndromes include Carney triad 
and Carney-Stratakis syndrome, as well as an association with desmoid tumors. Tumor biol-
ogy and behavior occur along a spectrum from benign spindle cell nodules to aggressive 
sarcomas, however, most GISTs, particularly gastric GISTs, are benign.
2. Pathobiology
2.1. Histopathology
From a histologic standpoint, GISTs can be divided into three main subtypes based on their 
microscopic appearance. The most common subtype is spindle cell (70%), followed by epi-
thelioid (20%), and mixed (10%) subtypes [15]. The spindle cell subtype demonstrates KIT or 
PDGFRα proto-oncogene mutations in the vast majority of cases, and most commonly affects 
individuals in their fifth and sixth decades of life [15, 17]. Due to these molecular expres-
sions, the spindle cell subtype responds well to treatment with Imatinib mesylate (Gleevec ®), 
resulting in a better overall prognosis. The epithelioid subtype is less common, and often 
seen in a younger, predominantly female population, and more commonly arises from the 
stomach [15, 18]. In addition, this subtype often lacks KIT and PDGFRα proto-oncogene 
mutations, and often demonstrated lymphatic metastases, resulting in a poorer prognosis 
when compared to the spindle cell subtype. It is critical to assess the number of mitoses per 
50 high-power fields (HPF) during microscopic analysis as it is an important prognostic indi-
cator, along with tumor size.
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2.2. Molecular biology
The identification of the KIT proto-oncogene by Hirota et al. in 1998 led to significant advances 
in the understanding of GIST molecular pathogenesis and set the stage to allow for break-
throughs in the treatment of this disease. A major revolution in the treatment of GISTs began 
with the introduction of imatinib mesylate (Gleevec®), a tyrosine kinase inhibitor (TKI) with 
activity against both KIT and PDGFRα proto-oncogene mutations. Before the advent of TKI 
therapy, GISTs were generally thought to be resistant to drug therapy, due to the ineffective-
ness of traditional chemotherapy regimens.
Over the past decade, with more frequent use of imatinib therapy in GISTs, medication resis-
tance in KIT-mutated GISTs is being more frequently encountered. This resistance is classified 
as either primary or secondary depending on whether they have been on treatment for less 
than 6 months or greater than 6 months, respectively. Different types of KIT proto-oncogene 
mutations have been identified, and determination of the specific mutation has been shown 
to predict the tumor response to tyrosine kinase inhibitor therapy. Most KIT proto-oncogene 
mutations involve exon 11 (75%), and portend a better prognosis due to a favorable response 
to tyrosine kinase inhibitor therapy [8, 19]. The majority of familial cases of GIST also tend 
to have exon 11 mutations. Another subset of patients harbor mutations involving exon 9, 
and is characterized by poor responsiveness to tyrosine kinase inhibition therapy, a shorter 
progression-free interval, and decreased overall survival. This subset is most frequently seen 
in non-gastric GISTs, and while traditional imatinib therapy shows limited efficacy, high-dose 
imatinib or sunitinib malate (Sutent®), a multiple tyrosine kinase receptor inhibitor, has had 
significant treatment success [20]. The exon 18 D842V mutation is the most common PDGFRα 
proto-oncogene mutation, and demonstrates resistance to tyrosine kinase inhibitor therapy, 
portending a poor prognosis.
Approximately 75–80% of GISTs harbor mutations in the KIT proto-oncogene, and approxi-
mately 10% of GISTs have a gain-of-function mutation in the PDGFRα tyrosine kinase recep-
tor (Table 1) [21]. While the vast majority of GISTs demonstrate mutations in KIT or PDGFRα, 
the remaining 10–15% do not have mutations in these exons, and are known as wild-type 
(WT) genotypes. These WT genotypes are characteristically very resistant to tyrosine kinase 
inhibition therapy. Almost 10% of WT GISTs harbor a BRAF V600E mutation on exon 15, and 
are more commonly seen in small intestine GISTs [22]. Secondary resistance in patients who 
have been on imatinib therapy for over 6 months commonly occurs due to secondary KIT 
proto-oncogene mutations involving exon 13 and 14, or from mutations involving other tyro-
sine kinases [23]. These secondary mutations are more frequently encountered with epitheli-
oid or mixed histology and have a predilection for lymphatic metastasis, portending a poor 
prognosis [15, 24, 25]. More recent studies on WT GISTs have revealed defects in the Krebs 
cycle enzyme succinate dehydrogenase (SDH), due to either a mutation or abnormal gene 
methylation, with WT GISTs now commonly being referred to as SDH-deficient GISTs [26, 27].
Numerous receptors and markers have been found to be associated with GISTs. KIT and 
PDGFRα mutations occur in up to 95% of cases, followed by expression of CD34 (60–70%), 
smooth muscle actin (ACAT2-30–40%), S100 (5%), desmin (DES-1–2%) and keratin (1–2%) 
[28–30]. More recently, gene microarray analyses have identified additional markers for 
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GIST. The most notable of these is the DOG1 (Discovered on GIST-1) gene, which has been 
identified in 97% of all GISTs, and expresses a calcium-gated protein known as anoctinin-1 
[31]. When used along with KIT, DOG1 has allowed up to 100% sensitivity in GIST detection 
and has also been found to be highly specific for GISTs [32].
2.3. Gross pathology
GISTs show significant size variation, ranging from millimeters in size to well over 20 cm [33]. 
The tumors originate from muscle rather than epithelium, and are often friable. Tumors are 
typically well-circumscribed with intact overlying mucosa, but may be nodular or ulcerated, 
and may occasionally have a pseudocapsule. As the tumor increases in size, it may outgrow its 
blood supply and demonstrate necrosis, cystic degeneration or hemorrhagic foci. It is necessary 
to clearly delineate tumor size, as it is a critical anatomic prognostic indication, along with the 
number of mitoses per 50 HPF [16, 27]. A size greater than 5 cm and a mitotic index greater than 5 
per 50 HPF correlates with aggressive tumor behavior and a poorer prognosis. A risk assessment 
scheme based on several large series published by Miettinen et al. demonstrates that for gastric 
GISTs with a mitotic index 5 per 50 HPF or lower, tumor sizes of 2–5, 5–10 and >10 cm resulted 
in metastasis or tumor-related death in 1.9, 3.6 and 10% of patients, respectively. Similarly, for 
gastric GISTs with a mitotic index of more than 5 per 50 HPF, tumor sizes of 2–5, 5–10 and >10 cm 
resulted in metastasis or tumor-related death in 16, 55 and 86% of patients, respectively [34, 35].
2.4. Micro-GIST
As imaging techniques improve and newer modalities such as endoscopic ultrasound (EUS) 
are utilized more frequently, small asymptomatic GISTs are being identified in the stomach 
wall, and are often under 1 cm in size. The term micro-GIST as described by Scherubl et al. 
Genetic Type Distribution Imatinib Response Features
KIT mutations
-Exon 9 SB/Colon High-dose imatinib Biologically aggressive
-Exon 11 All sites Responsive Longer event-free and overall survival;
Common in Familial GISTs; Deletions associated 
with malignant course
Duplications favorable
-Exon 13 All sites Responsive Spindle cell subtype; More common in SB
-Exon 17 All sites Responsive Spindle cell subtype;
PDGFRα mutations
-Exon 12 All sites Responsive Epithelioid subtype; Indolent course; More 
common in stomach
-Exon 14 Stomach Responsive
-Exon 18 D842V Stomach, E-GIST Resistant -Exon 18 (non-D842V) occurs in all sites
Table 1. Molecular classification of GISTs.
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has been found to be pathobiologically different from GISTs that become clinically significant. 
They have a very low proliferative rate and have different KIT mutations than those typically 
seen on larger tumors, with no reported progression of these tumors [36–38].
3. Diagnosis
The majority of GIST cases present with vague, non-specific symptoms, with up to 25% being 
diagnosed incidentally on imaging studies performed or other abdominal pathologies or 
trauma [39]. Specific symptoms often depend on the location of the tumor, tumor size, and 
presence of metastatic disease. The most common symptoms are GI bleeding, vague abdomi-
nal discomfort, and an abdominal mass, with other symptoms including abdominal pain, 
nausea, vomiting anorexia and early satiety. GISTs tend to displace adjacent structures rather 
than invade them, and because of their submucosal origin, they can reach comparatively 
larger sizes before becoming symptomatic. GISTs with high mitotic rates tend to quickly 
outgrow their blood supply, and can develop a necrotic core, increasing the risk of rupture, 
fistulization, and intraperitoneal hemorrhage. Specific to their location, GISTs can result in 
dysphagia in esophageal cases, gastric outlet obstruction with gastric cases, obstructive jaun-
dice in tumors of duodenal origin, and can act as a lead point for intussusception and small 
bowel obstruction [40–42]. A high index of suspicion remains paramount for accurate pre-
operative diagnosis given the rarity of this condition.
Multiple diagnostic and treatment guidelines have been published on GIST, including the 
National Comprehensive Cancer Network (NCCN) and the European Society of Medical 
Oncology (ESMO) guidelines. A GIST is suspected whenever a well-circumscribed mural or 
extramural, submucosal mass of any size is identified in the distal esophagus, stomach or 
small intestine, whether through imaging studies, at the time of surgery, during endoscopy, 
or on pathology analysis. It is critical to keep GIST in the differential diagnosis of any mass 
found in the alimentary canal from esophagus to rectum. GISTs remain the most common 
mesenchymal tumors of all sections of the GI tract with the exceptions of the esophagus, 
colon, and rectum, where leiomyomas are more common.
The imaging study of choice for initial evaluation of a GIST is a computed tomography (CT) 
scan of the abdomen and pelvis using oral and intravenous contrast enhancement, with arte-
rial and venous phases. GISTs will typically appear as a well-circumscribed, enhancing mass 
arising from the gastric or intestinal lumen. Large GISTs, which have outgrown their blood 
supply and have areas of necrosis, may appear as heterogeneously enhancing masses on CT 
imaging. It should be noted that CT Imaging in the setting of inadequate gastric distension 
can make it difficult to identify small GISTs. Even in patients with prior endoscopic imaging, 
a baseline CT scan is still necessary to determine full tumor extent and to evaluate for liver 
and peritoneal metastatic disease.
Routine magnetic resonance imaging (MRI) is inferior to CT imaging for the initial evalua-
tion of a GIST due to the constant movement of the stomach, small bowel, and surrounding 
tissues. Results using MRI with diffusion-weighted imaging (DWI), however, may be com-
parable to PET/CT imaging [43]. MRI is indicated in evaluation of peri-ampullary and rectal 
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GISTs, and to further evaluate for metastatic liver disease, as lesions are occasionally isodense 
to liver parenchyma on CT. Neither MRI nor CT has been shown to reliably predict tumor 
invasion into surrounding structures.
Positron Emission Tomography combined by CT imaging (PET/CT) plays a role in GIST 
diagnosis and management, as these tumors tend to show significant metabolic activity, and 
therefore lend themselves well to functional imaging with PET using 18F–fluorodeoxyglucose 
[44]. It is often used for assessment of metastatic disease and early metabolic changes, espe-
cially in response to tyrosine kinase inhibitor therapy, which may be informative in the set-
ting of neoadjuvant therapy. PET imaging may also be beneficial in detecting small omental 
metastases, which may not easily be identified on CT scans, as 18F–fluorodeoxyglucose is not 
taken up to any significant degree by normal small intestine or omentum. Recently, a large 
percentage of GISTs have been found to express somatostatin receptors, SSTR1 and SSTR2. 
This has created a role for somatostatin receptor scintigraphy in evaluation of GISTs, similar 
to its role in GI and pancreatic neuroendocrine tumors [45].
Endoscopy plays a significant role in the evaluation of GISTs, and provides a means of tis-
sue sampling for pathologic analysis. Upper GI endoscopy is used to evaluate tumors in the 
esophagus, stomach and duodenum, while colonoscopy is used to evaluate rectal and colon 
masses. For distal duodenal and jejunoileal masses, which are poorly accessible by traditional 
endoscopic techniques, there is a role for capsule endoscopy and for double-balloon enter-
oscopy in evaluating these lesions. Endoscopic ultrasound (EUS) has also been used in the 
evaluation of suspected GISTs. They are visualized as circumscribed hypodense lesions deep 
to the mucosa. Tumors with irregular borders, size greater than 4 cm, as well as significant 
echogenic foci and cystic spaces have been found to correlate with malignant behavior [46].
Endoscopy and EUS offer the advantage of being able to perform a tissue biopsy at the time 
of the procedure. Unfortunately, endoscopic mucosal biopsies are successful in only 20–30% 
of cases, even in GISTs which involve the mucosa or the superficial submucosa. EUS-guided 
fine-needle aspiration cytology, however, has demonstrated more favorable results, with a 
diagnostic yield of 76%, and EUS-guided core biopsies with a yield of 97% [47, 48]. While 
there is a role for percutaneous biopsies, particularly in large tumors, many institutions have 
demonstrated superior yields from EUS-guided biopsies [49, 50]. It should be noted, however, 
that if imaging studies are strongly suggestive of a mesenchymal tumor which appears to be 
resectable, it is usually not necessary to obtain a tissue diagnosis preoperatively. Conversely, 
if metastatic disease is evident, or if resectability is questionable, a tissue diagnosis is required 
to plan for immunohistochemical analysis and targeted molecular therapy.
The pathologic diagnosis of GIST is defined by the morphology, ultrastructure and immu-
nohistochemistry findings. These tumors are mesenchymal in origin and have spindle cell, 
epithelioid cell or mixed histology with variable mitotic activity, which along with tumor size 
are of prognostic significance. Immunohistologically, up to 95% of GISTs stain positive for 
KIT (CD117). Additional staining for markers such as PDGFRα, PI3K, CDKN2A and DOG1 
can also be performed. In addition to tumor size and mitotic activity, several pathologic and 
immunohistochemical findings have been shown to affect prognosis and predict recurrence, 
including Ki67 proliferation index, presence of diffuse mucosal involvement, tumor rupture, 
tumor location, completeness of resection, aneuploidy, and telomerase expression [42, 51–57].
Gastrointestinal Surgery - New Technical Proposals80
4. Management
4.1. Primary GIST
Definitive surgical resection in patients with primary, localized GISTs remains the only 
chance for cure [58]. The surgical approach to GISTs takes into consideration the typical 
tumor growth patterns and tends to follow the general principles of management of sarco-
mas. It is uncommon for GISTs to have lymph node spread, and they usually do not demon-
strate significant intramural extension. Given the somewhat predictable pattern of growth 
and the infrequency of lymph node involvement, extensive tumor resection and lymph node 
dissections can usually be avoided unless there is gross lymphadenopathy present. Surgical 
management typically involves a wedge resection of the stomach, or a segmental small bowel 
resection for small bowel GISTs.
The best long-term results were traditionally thought to be achieved after complete resection 
with microscopically negative margins (R0 resection), typically via resections with 1–2 cm 
margins. Although the goal of surgical resection should always be to obtain an R0 resec-
tion, recent studies have demonstrated that tumor size and inherent biologic status play a 
greater role in predicting survival than do microscopic margins. It is now generally accepted 
that grossly negative margins (R1) do not lead to significant differences in recurrence-free 
survival(RFS) when compared to R0 resections, irrespective of the use of adjuvant therapy 
[11, 59]. Gross resection to negative margins is generally achievable in 85% of localized, pri-
mary GISTs, with cases of adjacent organ involvement surgically approached with en bloc 
resection. The American College of Surgeons Oncology Group (ACOSOG) Z9000 and Z9001 
studies, in addition to demonstrating no difference in RFS between R0 and R1 resections, 
demonstrated that surgical resection of tumors ≥3 cm was curative in 70% of patients at long-
term follow-up, underscoring the pivotal role of surgical resection with curative intent in 
medically fit patients. The NCCN guidelines reflect these results, with recommendations to 
resect all GISTs with a size over 2 cm.
GISTs involving the colon and small intestine tend to be more aggressive, and warrant resec-
tion regardless of size, whereas for gastric GISTs smaller than 2 cm, endoscopic surveillance 
or serial imaging seems to be a reasonable option. A 2011 study by Kim et al. looking retro-
spectively at 989 patients with small subepithelial gastric tumors less than 3 cm in size dem-
onstrated that only 8.5% of tumors had significant growth at median follow-up of 24 months. 
Twenty-five patients underwent tumor resection due to concerning growth or finding on 
imaging, of which 19 were GISTs, and only 3 of these were considered high-risk, with 4 classi-
fied as intermediate-risk [60]. The high incidence of small gastric GISTs is reflected in autopsy 
series where the incidence of subcentimeter gastric GISTs was as high as 22.5% in persons 
over 50 years old in a German study, and the incidence of microscopic GISTs was as high as 
35% in gastric resection specimens for gastric cancer in a Japanese study [61, 62].
Gross resection margins of 2–3 cm for small bowel GISTs, and a microscopically free margin 
of only several millimeters in gastric GIST wedge resections is generally considered adequate. 
Greater gastric resections, including partial or total gastrectomy, are usually reserved for 
larger GISTs, or those which preclude wedge resection based on location [63].
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Rectal GISTs remain uncommon, however consideration may be given to endoscopic resection 
based on size, extent, and anatomic relationships. While not common practice, laparoscopic 
resection of small GISTs, particularly those which are gastric in origin, has been described 
with good outcomes [64, 65].
Incomplete (R2) resections of GISTs are generally reserved for surgery with palliative 
intent to alleviate symptoms related to pain, bleeding, or mass effect. Despite the high 
rate of successful complete gross tumor resection, there has been a historically high recur-
rence rate of over 50%, with an associated 5-year mortality rate of approximately 50% [11, 
42, 53]. The median time to recurrence after an adequate R0 resection has been found to 
be between 19 and 25 months, with recurrences typically involving the liver and perito-
neum, and is usually not amenable to a repeat resection [11, 53, 66]. GISTs are usually very 
vascular with a fragile pseudocapsule. Careful intraoperative handling of the tumor is 
therefore essential to minimize the risk of tumor rupture, which often results in peritoneal 
recurrence [53].
Open resection of gastric and small intestine GISTs has been the traditional approach to 
operative management, however, minimally invasive approaches are now being utilized with 
good outcomes. Laparoscopic resection of gastric and some small intestine GISTs is being 
attempted with increased frequency, and allows for many of the benefits of laparoscopic sur-
gery, including decreased postoperative pain, a shorter hospital length-of-stay, faster return 
to work and functional independence, and a better cosmetic outcome [67–71]. In addition to 
open surgical options for colon and rectal GISTs, endoscopic resection in cases of small rectal 
GISTs may also be considered. More recently, laparoscopic and endoscopic cooperative sur-
gery (LECS) has been employed in resection of gastric GISTs, where the mucosal dissection of 
tumors that protrude intraluminally is performed endoscopically [72].
4.2. Advanced GIST
Despite adequate surgical resection of localized GISTs, not all operations are curative. Many 
studies have reported high recurrence rates, up to 50%, after complete tumor resection [11, 
40]. The initial sites of recurrence are most frequently the liver (50%), peritoneum (50%), or 
both (20%), with bone and lung metastases often occurring later [73]. Both liver and perito-
neal involvement in this setting tend to be diffuse and multifocal, with surgery playing a very 
limited role in the face of recurrent or metastatic disease. Historically, conventional chemo-
therapy and radiotherapy regimens have been ineffective in treating advanced GISTs [74]. 
The advent of targeted molecular therapy has revolutionized the treatment of GISTs, with 
tyrosine kinase inhibitors such as imatinib playing a pivotal role in management.
The clinical value of imatinib for high-risk patients and those with advanced disease was 
established in the ACOSOG Z9000 and Z9001 trials. The ACOSOG Z9000 trial demonstrated a 
remarkable improvement in the survival rate of high-risk patients (tumor size ≥10 cm, tumor 
rupture or <5 peritoneal metastases) who had undergone complete surgical resection of KIT-
positive GISTs [75]. The ACOSOG Z9001 trial was a randomized trial comparing the use of ima-
tinib to a placebo in moderate risk GISTs (tumor size ≥3 cm). There was a significant increase 
in RFS in the imatinib group, though overall survival was no different in the short-term [76].
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Patients receiving imatinib therapy show changes in metabolic activity on PET scans within 
hours, however, a decrease in tumor size often takes several weeks to months, and tumors may 
even increase in size initially. For these reasons, the traditional World Health Organization 
(WHO) and Response Evaluation Criteria in Solid Tumors (RECIST) criteria are not ideal in 
evaluating response to imatinib therapy in GIST. This response to imatinib therapy is better 
evaluated by contrast-enhanced CT scans using the Choi criteria, which evaluates for both a 
decrease in tumor size as well as the tumor density [77, 78]. The use of PET scans have also 
Figure 1. A schematic overview of the approach to management of gastrointestinal stromal Tumors (GISTs). (Adopted 
from [40]).
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been shown to be very sensitive in evaluating tumor response, given the early changes in 
tumor metabolic activity [79]. The tumor response to imatinib therapy at day 8 on PET scans 
have been shown to correlate with 1-year prognosis in unresectable GISTs [79, 80]. Imatinib 
use in the neoadjuvant setting has not been studied as extensively as adjuvant therapy, but 
remains very useful in locally advanced or borderline resectable tumors, and tumors in loca-
tions where tumor downsizing may allow for a less morbid operation.
Resistance to imatinib therapy unfortunately occurs, and may be of two types as mentioned 
earlier. Primary resistance occurs in patients who either never had an initial response, or who 
show disease progression within 6 months of initiating therapy, while secondary resistance 
occurs in those who show disease progression after 6 months of therapy. This latter group 
often acquires mutations in KIT or PDGFRα that interfere with imatinib activity [81, 82]. 
Sunitinib and regorafenib are both newer FDA approved agents which block multiple tyro-
sine kinase receptors for use in GIST patients with disease progression or intolerance to ima-
tinib. Several other tyrosine kinase inhibitors, including nilotinib, masatinib, dasatinib and 
sorafenib have been used in cases of resistance to imatinib and sunitinib or in patients with 
intolerance, however, their role in the management of GISTs continues to be investigated. A 
schematic overview of the approach to management of GISTs is shown in Figure 1 [40].
5. Surveillance
Long-term follow-up is necessary in all patients with GISTs, due to their unpredictable biolog-
ical behavior. Most recurrences tend to occur within the first 3–5 years, and surveillance rec-
ommendations take this into account. Recommendations by the NCCN include performing a 
history, physical examination, and a contrast-enhanced CT scan of the abdomen and pelvis every 
3–6 months for 3–5 years, and then annually thereafter [8]. Recommendations from the European 
Society of Medical Oncology (ESMO) are based on tumor size and mitotic activity [83]. High-risk 
tumors (size ≥5 cm and mitoses ≥5/50 HPF) require a CT scan of the abdomen and pelvis every 
3–4 months for 3 years then every 6 months for 2 years thereafter, while tumors <5 cm in size with 
a mitotic rate of <5/50 HPF should have a CT scan of the abdomen and pelvis every 6 months for 
5 years.
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